Characterization and comparability of biosimilars: A filgrastim case of study and regulatory perspectives for Latin America

Characterization and comparability of biosimilars: A filgrastim case of study and regulatory perspectives for Latin America

Background: Developing countries have an estimate of ten times more approved biosimilars than developed countries. This disparity demands the need of an objective regulation that incorporates health policies according to the technological and economical capabilities of each country. One of the chall...

Full description

Bibliographic Details
Main Authors:	Karina Mendoza-Macedo, Alexis J. Romero-Díaz, Mariana P. Miranda-Hernández, Víctor R. Campos-García, Nancy D. Ramírez-Ibañez, L. Carmina Juárez-Bayardo, Karen Moreno-Duran, Miriam S. Cedillo-Robles, Nestor O. Pérez, Helgi Jung-Cook, Luis F. Flores-Ortiz, Emilio Medina-Rivero
Format:	Article
Language:	English
Published:	Elsevier 2016-11-01
Series:	Electronic Journal of Biotechnology
Subjects:	Bio therapeutic Comparability Critical quality attributes Developing countries Generics Health policies High quality biosimilars Regulation
Online Access:	http://www.sciencedirect.com/science/article/pii/S0717345816300987

Similar Items

Biosimilars in the management of neutropenia: focus on filgrastim
by: Caselli D, et al.
Published: (2016-02-01)

Generic and biosimilar medicines: quid?
by: Steven Simoens
Published: (2012-12-01)

Biosimilars: presumption of guilt
by: Marina Vladimirovna Shestakova, et al.
Published: (2011-12-01)

Options to optimize the access to biosimilars: analysis and solutions
by: O. V. Kirsanova, et al.
Published: (2018-05-01)

From generic to biosimilar drugs: why take an innovative pace?
by: Fereshteh Barei, et al.
Published: (2012-12-01)

Clinical Utilization of Generic Drugs and Biosimilars for Ulcerative Colitis Treatment: Insights from a Nationwide Database Study in Japan
by: Rintaro Moroi, et al.
Published: (2024-01-01)

Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars
by: Ali M. Alsamil, et al.
Published: (2021-02-01)

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
by: Choi C, et al.
Published: (2018-08-01)

INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW
by: D. G. Tolkacheva, et al.
Published: (2018-02-01)

INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW
by: D. G. Tolkacheva, et al.
Published: (2018-02-01)

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
by: Schwartzberg LS, et al.
Published: (2018-09-01)

Nocebo in Biosimilars and Generics in Neurology: A Systematic Review
by: Ioanna Spanou, et al.
Published: (2019-07-01)

A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients
by: Roberto Hegg, et al.

Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
by: Kerry Mansell, et al.
Published: (2019-11-01)

Analytical Similarity Assessment of Biosimilars: Global Regulatory Landscape, Recent Studies and Major Advancements in Orthogonal Platforms
by: Neh Nupur, et al.
Published: (2022-02-01)

Main concepts on bioequivalence and biosimilarity in the Chilean legislation, and current controversies on drug interchangeability
by: Jana Stojanova, et al.
Published: (2020-01-01)

Biosimilars and Switching: What Is Your Perspective?
by: Sandoz
Published: (2017-08-01)

Biosimilars
by: Emel Bülbül Başkan
Published: (2022-04-01)

Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis
by: Rocío Parody, et al.
Published: (2020-05-01)

Authorisation of Non-Innovator Biotherapeutic (Biosimilar) Products in the USA
by: A. A. Soldatov, et al.
Published: (2019-03-01)

RETRACTED: Biosimilars - advantages and prospects
by: A. A. Lidzhiyeva, et al.
Published: (2018-02-01)

On the Regulatory Approval Pathway of Biosimilar Products
by: Jun Wang, et al.
Published: (2012-03-01)

Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia
by: Otremba B, et al.
Published: (2018-10-01)

Biosimilars: development and investigation using achievements in modern biotechnology
by: R. R. Niyazov, et al.
Published: (2021-02-01)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
by: Ioana Gherghescu, et al.
Published: (2020-12-01)

Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study)
by: Henri Roché, et al.
Published: (2018-11-01)

Biosimilar insulins in international and domestic practice of pharmacist
by: I. O. Vlasenko, et al.
Published: (2022-02-01)

An Overview of Biosimilars—Development, Quality, Regulatory Issues, and Management in Healthcare
by: Filipa Mascarenhas-Melo, et al.
Published: (2024-02-01)

Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review
by: Arnold G. Vulto, et al.
Published: (2020-11-01)

G-CSF filgrastim biosimilar-Sandoz reduces the incidence of febrile neutropenia in patients receiving chemotherapy regimens with rest periods not exceeding 14 days: A French, multicenter, prospective, non-interventional study
by: Jean-Marc Phelip, et al.
Published: (2023-01-01)

The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy
by: Eva Rahman Kabir, et al.
Published: (2019-08-01)

Dynamics of prices and consumption of anticancer drugs in Russia after their generics and biosimilars became available
by: F. V. Gorkavenko, et al.
Published: (2019-07-01)

Los biológicos y los biosimilares
by: Carlos Rios Acosta
Published: (2017-06-01)

Ten years of biosimilar recombinant human growth hormone in Europe
by: Saenger P
Published: (2017-05-01)

Similarity assessment of quality attributes of biological medicines: the calculation of operating characteristics to compare different statistical approaches
by: Thomas Stangler, et al.
Published: (2019-09-01)

BIOSIMILARS IN RHEUMATOLOGY
by: E. L. Nasonov
Published: (2017-01-01)

Generic orphan drug substitution: a critical analysis of global practices and Saudi Arabia’s perspective
by: Yousif S. Alakeel, et al.
Published: (2024-04-01)

New Quality-Range-Setting Method Based on Between- and Within-Batch Variability for Biosimilarity Assessment
by: Alexis Oliva, et al.
Published: (2021-06-01)

Triunfalismo del decreto de los Biosimilares
by: Carlo Vinicio Caballero Uribe
Published: (2014-01-01)

Biosimilars: potential implications for clinicians
by: Eleryan MG, et al.
Published: (2016-06-01)